Prognostic implication of ezrin expression in esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 104, Issue 5, 2011, Pages 538-543

  Xie, Jian Jun ^a   Xu, Li Yan ^a   Wu, Zhi Yong ^b   Zhao, Qing ^a   Xu, Xiu E ^a   Wu, Jian Yi ^a   Huang, Qiao ^a   Li, En Min ^a  

^a SHANTOU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

biomarker; ESCC; ezrin; prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; EZRIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CYTOPLASM; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOSKELETAL PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80052447922     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21909     Document Type: Article

References (25)

1. Pisani P, Parkin DM, Bray F, et al.: Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 870-873.
2. Lehrbach DM, Nita ME, Cecconello I,: Molecular aspects of esophageal squamous cell carcinoma carcinogenesis. Arq Gastroenterol 2003; 40: 256-261. (Pubitemid 38620421)
3. Katlic MR, Wilkins EW, Jr., Grillo HC,: Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1990; 99: 929-938. (Pubitemid 20162961)
4. Hagymasi K, Tulassay Z,: Genetic background of esophageal squamous cell carcinoma. Orv Hetil 2007; 148: 1795-1800. (Pubitemid 47527642)
5. Tachibana M, Kinugasa S, Hirahara N, et al.: Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg 2008; 34: 427-431.
6. Bretscher A, Edwards K, Fehon RG,: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586-599.
7. Hunter KW,: Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10: 201-204. (Pubitemid 38581790)
8. Bruce B, Khanna G, Ren L, et al.: Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007; 24: 69-78. (Pubitemid 46669242)
9. Curto M, McClatchey AI,: Ezrina-A metastatic detERMinant? Cancer Cell 2004; 5: 113-114.
10. Shen ZY, Xu LY, Li EM, et al.: Ezrin, actin and cytoskeleton in apoptosis of esophageal epithelial cells induced by arsenic trioxide. Int J Mol Med 2003; 12: 341-347.
11. Zeng H, Xu L, Xiao D, et al.: Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 2006; 54: 889-896. (Pubitemid 44106866)
12. Xie JJ, Xu LY, Xie YM, et al.: Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells. Int J Cancer 2009; 124: 2549-2558.
13. Gao SY, Li EM, Cui L, et al.: Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem 2009; 284: 7995-8004.
14. Zhang FR, Tao LH, Shen ZY, et al.: Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 2008; 56: 193-199.
15. McClatchey AI,: Merlin and ERM proteins: unappreciated roles in cancer development. Nat Rev Cancer 2003; 3: 877-883. (Pubitemid 37376984)
16. Khanna C, Wan X, Bose S, et al.: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-186. (Pubitemid 38524889)
17. Kim C, Shin E, Hong S, et al.: Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009; 41: 138-144.
18. Elliott BE, Meens JA, SenGupta SK, et al.: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005; 7: R365-R373.
19. Peng S, Fan S, Li X, et al.: The expression of ezrin in NPC and its interaction with NGX6, a novel candidate suppressor. Cancer Sci 2007; 98: 341-349. (Pubitemid 46195604)
20. MusiaÅ J, Sporny S, Nowicki A,: Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol 2007; 58: 235-243. (Pubitemid 351428300)
21. Sarriõ D, Rodríguez-Pinilla SM, Dotor A, et al.: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006; 98: 71-79. (Pubitemid 44050782)
22. Fiévet B, Louvard D, Arpin M,: ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta 2007; 1773: 653-660. (Pubitemid 46660175)
23. Martin TA, Harrison G, Mansel RE, et al.: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003; 46: 165-186. (Pubitemid 36452345)
24. Yu Y, Khan J, Khanna C, et al.: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004; 10: 175-181. (Pubitemid 38524888)
25. Wang G, Mao W, Zheng S,: MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 2008; 582: 3663-3668.